Matt Heck Co-Founder, President & Chief Executive Officer
Mr. Heck is the CEO and also a member of the Board of Directors. Prior to Sentynl, Mr Heck co-founded Victory Pharmaceuticals and served as its President and CEO and acted as a member of its Board of Directors. Formerly, Mr. Heck was Vice President of Sales at Biovail Pharmaceuticals, where he built and managed U.S. commercial operations that consisted of over 650 employees and had combined annual revenues from a portfolio of cardiovascular, anti-viral, CNS and respiratory products in excess of $300 million. Mr. Heck joined Biovail in 2000 when it acquired DJ Pharma, which he had joined at inception and served as Vice President of Sales. While at DJ Pharma, he built and managed a 300-person U.S. Sales team and was central to the integration and effective commercialization of a diverse portfolio of anti-infective and respiratory products that were acquired and in-licensed from different parties. Mr. Heck began his specialty pharmaceutical industry career Dura Pharmaceuticals (acquired by Elan), where he held a variety positions in Sales, Sales Management, Marketing and Managed Care Marketing. Prior to joining Dura, he managed key accounts at Dial Corp. Mr. Heck earned his B.A. in Marketing from the University of South Carolina. Presently, Mr. Heck also serves on the Board of Directors at Highland Therapeutics, Inc.
Daniel Stokely, CPA Executive Vice President & Chief Financial Officer
Mr. Stokely is the Executive Vice President and Chief Financial Officer. Previously, Mr. Stokely served in the roles of VP Finance / Chief Accounting Officer and Chief Financial Officer at Victory Pharmaceuticals. Prior to Victory, Mr. Stokely worked for Wireless Facilities, Inc. where he served in the role of Corporate Controller and Chief Accounting Officer. Previously, Mr. Stokely served in the role of Corporate Controller and Senior Director of Accounting for Dura Pharmaceuticals and its successor Elan Corporation. Mr. Stokely began his career as a CPA with Deloitte & Touche and received his B.S. in accounting from San Diego State University.
Michael Hercz, Esq. Senior Vice President, General Counsel & Chief Compliance Officer
Mr. Hercz is the General Counsel and Chief Compliance Officer. Mr. Hercz brings more than 19 years of legal, compliance and risk management experience to Sentynl. Prior to Sentynl, Mr. Hercz served as a Director in Deloitte & Touche’s Enterprise Risk Services Group where he advised Fortune 500 Life Sciences management teams on leading industry practices. Previously, Mr. Hercz was Vice President and Chief Compliance Officer of Victory Pharmaceuticals where he oversaw the company’s corporate compliance program and served as a member of the executive team. Prior to joining Victory, Michael spent nearly eight years with Amgen Inc. in a series of increasingly senior legal, compliance and risk management roles. Prior to joining industry, Michael practiced law at the global law firm Akin, Gump, Strauss, Hauer & Feld LLP and at Hooper, Lundy & Bookman Inc. where he counseled Life Science industry clients on a broad range of issues, from complex transactions to white collar criminal investigations. Mr. Hercz earned his B.A. in Psychology from the University of Pennsylvania and his J.D. from the University of Southern California.
Shawn Scranton, PharmD Chief Scientific Officer
Dr. Scranton is the Chief Scientific Officer. Dr. Scranton brings more than 20 years of clinical development experience to Sentynl. Most recently, Dr. Scranton served as the Vice President of Scientific Operations at Victory Pharmaceuticals, Inc, where he oversaw Clinical, Regulatory, Manufacturing and Medical Affairs functions, while bringing two new products to market and managing three pipeline development programs. Prior to Victory, Shawn was Senior Director of Translational Medicine for Kalypsys, Inc., where he contributed to non-clinical, regulatory, and clinical strategies that enabled the successful opening of NCE INDs, and conducting clinical programs in neuropathic pain and metabolic disease. Formerly, Dr. Scranton was Director of Clinical Development and program director of the SDX-101 program for Salmedix, Inc., which was acquired by Cephalon. He began his industry career as a Senior Clinical Research Scientist at Dura Pharmaceuticals after holding a series of academic positions at Baylor College of Medicine, where he served as a Principal Investigator on a number of industry and government-supported clinical trials. Dr. Scranton earned his Pharm.D. from the University of the Pacific School of Pharmacy, where he also completed a fellowship in cardiovascular pharmacology. He earned his B.A. in Animal Physiology from University of California, San Diego.
Darren Pincus Senior Vice President, Business Development
Mr. Pincus is the Senior Vice President, Business Development. Mr. Pincus is a highly experienced business development professional with a strong track record of successfully completed transactions. Prior to Sentynl, Mr. Pincus was Executive Director of Corporate and Business Development at Pacira Pharmaceuticals, where he was responsible for in-licensing, international out-licensing and pipeline initiatives. Previously, Mr. Pincus was Vice President of Corporate Development for EKR Therapeutics where he led the Corporate Development function. Prior to EKR, Mr. Pincus served in senior business development roles at Alpharma, Savient Pharma, and PLIVA / Odyssey Pharma. Mr. Pincus began his career in the Global Healthcare Corporate Finance practice of Arthur Anderson. Mr. Pincus earned his B.S. in Finance from the Pennsylvania State University.